Company intelligence / Profile preview

Cybrexa Therapeutics

New Haven, Connecticut, United Statescybrexa.com ↗

Ownership: Private
Development stage: Phase 2

Overview

CBX‑12 has demonstrated a favorable safety profile and promising activity across several advanced or metastatic solid tumors. In a completed Phase 1 trial, CBX‑12 showed broad antitumor activity—including a reported 40% response rate in TOP1-naïve ovarian cancer patients—and was well tolerated. Preclinical data show robust efficacy as monotherapy and synergy with standard-of-care treatments. The company’s alphalex PDCs have shown complete tumor suppression in preclinical models and induction of durable anti-tumor immunity.

Therapeutic areas: Oncology
Modalities: Peptide-drug conjugates (PDCs)small molecule anti-cancer drugs
Industry: Biotech

Drug pipeline

5 assets

alphalex exatecan

4 more assets in the full pipeline.

Request access →

Partnerships

Previously had an acquisition agreement with Exelixis for CBX‑12 that was later terminated; no current major pharma partnerships disclosed as of May 2025.Collaboration with National Cancer Institute planned for future trials.

Beyond the preview

Go deeper on Cybrexa Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cybrexa Therapeutics.

Explore the full profile